Drawing for RETHINK DEPRESSION

USPTO serial 87892560

RETHINK DEPRESSION

Reviewed by CopyMark Law Group

Reg. 5831155Status 710
Filing date
Status date
Registration date
Aug 13, 2019
Examiner
LE, KHANH M
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with RETHINK DEPRESSION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maren C. Perry

Maren C. Perry King & Spalding LLP1185 Avenue of the AmericasNew York, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
005Vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and chemical dependency; diagnostic agents, reagents, preparations and substances for medical purposesSECTION 8 - CANCELLED—
009Downloadable electronic publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of pharmaceutical research and development, disease awareness, medical clinical studies, pharmaceutical tests and trials, diagnostic medicine, medicine, pharmaceuticals, disorders, diseases, clinical or medical treatment and prevention; software for medical and pharmaceutical information, education and sales activities, namely, software featuring audio and video information for pharmaceutical representatives on the subject of pharmaceuticals for use in the treatment of medical conditions; software for analyzing medical and pharmaceutical information and featuring information on disease symptoms for use in promoting disease awareness; software, namely, application software for mobile devices for analyzing medical and pharmaceutical information; apparatus and instruments, namely, computers for analyzing medical and pharmaceutical information in the fields of research and development, science, clinical studies, medical clinical tests and trials, diagnostic medicine, pharmaceuticals, disorders, diseases, treatment and prevention; electronic downloadable publications, namely, magazines, journals, teaching and educational materials in the field of pharmaceutical research and development, science, medical clinical studies, pharmaceutical tests and trials, diagnostic medicine related to clinical or medical treatment and preventionSECTION 8 - CANCELLED—
041Educational services, namely, conducting seminars in the field of pharmaceuticals and disease awareness; providing of training in the field of pharmaceuticals and disease awareness; arranging and conducting seminars, conferences, symposiums, training workshops and courses in the field of pharmaceuticals and disease awareness; educational training services in the fields of pharmaceutical research and development, medical clinical tests and trials in the field of pharmaceuticals, diagnostic medicine related to the treatment and prevention of diseases and disorders; providing the aforementioned services electronically, on-line, via cable or Internet or other electronic media; arranging and conducting expert forums, namely, on-line training programs in the field of pharmaceuticals; providing on-line, non-downloadable publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of pharmaceutical research and development, science, medical clinical studies in the field of pharmaceutical tests and trials, diagnostic medicine, pharmaceuticals, disorders, diseases awareness, treatment and prevention related to the assessment of cognitive functions; providing educational assessment services in the field of cognitive functions through on-line non-downloadable screening toolsSECTION 8 - CANCELLED—
042Pharmaceutical research and development; scientific and technological services, namely, scientific testing and research related to medical disorders, medical diseases and medical prevention; scientific and technological services, namely, scientific testing and research related to the central nervous system and central nervous system related disorders, pharmaceuticals and disease awareness; medical and clinical research, namely, clinical research and conducting clinical trials for others in the field of pharmaceuticals; diagnostic research and tests in the field of pharmaceutical research; providing online non-downloadable screening software for assessing cognitive functionsSECTION 8 - CANCELLED—
044Medical and clinical healthcare, therapeutic healthcare, healthcare services and healthcare information services; services in the field of psychiatry, psychology, neurology and central nervous system diseases and disorders, namely, healthcare services in the field of psychiatry, psychology and neurology and central nervous system diseases and disorders; providing healthcare information in the field of disease awareness and medical and pharmaceutical preparations and substances related to central nervous system and brain disorders; healthcare and medical services related to central nervous system and brain disorders, diseases and pharmaceuticals; providing for medical and medicinal information in the field of diagnostic, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; providing on-line medical data and analyses designed to provide patients and clients customized information regarding medical dosage, diagnosis, disease awareness, therapeutic issues and medical managementSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 27, 2026C8..CANCELLED SEC. 8 (6-YR)—
Aug 13, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Mar 22, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 22, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Mar 22, 2024EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Mar 22, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 22, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 13, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 28, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 28, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 8, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 25, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 4, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 4, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 4, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 12, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 12, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 12, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 17, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 17, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 13, 2018ALIEASSIGNED TO LIE—
Sep 4, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 26, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 21, 2018DOCKASSIGNED TO EXAMINER—
May 5, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 4, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 28, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance